CYTO
Price:
$0.499
Market Cap:
$1.66M
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treat...[Read more]
Industry
Biotechnology
IPO Date
2014-08-06
Stock Exchange
NASDAQ
Ticker
CYTO
According to Altamira Therapeutics Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 0.27. This represents a change of -260.31% compared to the average of -0.17 of the last 4 quarters.
The mean historical PE Ratio of Altamira Therapeutics Ltd. over the last ten years is -3.30. The current 0.27 PE Ratio has changed -919.13% with respect to the historical average. Over the past ten years (40 quarters), CYTO's PE Ratio was at its highest in in the December 2021 quarter at 1.00. The PE Ratio was at its lowest in in the September 2014 quarter at -20.16.
Average
-3.30
Median
-1.54
Minimum
-11.80
Maximum
-0.15
Discovering the peaks and valleys of Altamira Therapeutics Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 28.42%
Maximum Annual PE Ratio = -0.15
Minimum Annual Increase = -87.79%
Minimum Annual PE Ratio = -11.80
Year | PE Ratio | Change |
---|---|---|
2023 | -0.20 | 28.42% |
2022 | -0.15 | -87.79% |
2021 | -1.26 | -25.93% |
2020 | -1.70 | 23.80% |
2019 | -1.37 | 10.75% |
2018 | -1.24 | -42.64% |
2017 | -2.16 | -11.25% |
2016 | -2.44 | -77.06% |
2015 | -10.63 | -9.97% |
2014 | -11.80 | -8.18% |
The current PE Ratio of Altamira Therapeutics Ltd. (CYTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.54
5-year avg
-0.94
10-year avg
-3.30
Altamira Therapeutics Ltd.’s PE Ratio is greater than Pyxis Oncology, Inc. (-4.52), greater than Zura Bio Limited (-8926.32), greater than eFFECTOR Therapeutics, Inc. (-0.00), greater than Elevation Oncology, Inc. (-0.92), greater than Immix Biopharma, Inc. (-2.81), greater than Enveric Biosciences, Inc. (-0.34), greater than Palisade Bio, Inc. (-0.22), less than CNS Pharmaceuticals, Inc. (0), greater than ZyVersa Therapeutics, Inc. (-0.00), greater than VectivBio Holding AG (-0.05), greater than AVROBIO, Inc. (-7.94), less than null (2.07),
Company | PE Ratio | Market cap |
---|---|---|
-4.52 | $262.65M | |
-8926.32 | $292.09M | |
-0.00 | $941.00 | |
-0.92 | $38.41M | |
-2.81 | $51.06M | |
-0.34 | $4.21M | |
-0.22 | $3.37M | |
0 | $4.34M | |
-0.00 | $1.50M | |
-0.05 | $1.06B | |
-7.94 | $5.24M | |
2.07 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Altamira Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Altamira Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Altamira Therapeutics Ltd.'s PE Ratio?
How is the PE Ratio calculated for Altamira Therapeutics Ltd. (CYTO)?
What is the highest PE Ratio for Altamira Therapeutics Ltd. (CYTO)?
What is the 3-year average PE Ratio for Altamira Therapeutics Ltd. (CYTO)?
What is the 5-year average PE Ratio for Altamira Therapeutics Ltd. (CYTO)?
How does the current PE Ratio for Altamira Therapeutics Ltd. (CYTO) compare to its historical average?